Ruben A Mesa Selected Research

Primary Myelofibrosis (Myelosclerosis)

1/2022	Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.
1/2022	Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts.
1/2022	Novel strategies for challenging scenarios encountered in managing myelofibrosis.
5/2021	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial.
5/2021	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial.
4/2021	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
1/2021	TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
10/2020	Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.
6/2020	Management of myelofibrosis after ruxolitinib failure.
1/2020	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ruben A Mesa Research Topics

Disease

96	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 03/2002
46	Neoplasms (Cancer) 01/2022 - 02/2002
35	Splenomegaly 04/2021 - 06/2002
27	Anemia 04/2021 - 07/2004
26	Polycythemia Vera 12/2022 - 08/2002
21	Essential Thrombocythemia 12/2022 - 04/2005
18	Cytopenia 06/2020 - 08/2002
14	Fatigue 12/2020 - 03/2006
13	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2004
9	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 07/2005
9	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2017 - 08/2003
8	Leukemia 01/2021 - 03/2006
8	Myeloproliferative Disorders (Myeloproliferative Disorder) 01/2019 - 08/2003
6	Fibrosis (Cirrhosis) 01/2021 - 03/2002
5	Pain (Aches) 04/2019 - 08/2005
5	Disease Progression 05/2017 - 02/2005
5	Thrombocytosis (Thrombocythemia) 09/2010 - 05/2002
4	Blast Crisis (Blast Phase) 10/2020 - 09/2012
4	Hematologic Neoplasms (Hematological Malignancy) 04/2012 - 02/2002
3	Philadelphia Chromosome 10/2017 - 07/2011
3	Fever (Fevers) 05/2017 - 07/2013
3	Polycythemia (Erythrocytosis) 06/2013 - 08/2002
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2012 - 06/2007
3	Leukocytosis (Pleocytosis) 09/2009 - 07/2004
2	Inflammation (Inflammations) 04/2021 - 01/2015
2	Obesity 01/2020 - 04/2014
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2017
2	Dyspnea (Shortness of Breath) 04/2019 - 01/2017
2	Pruritus (Itching) 04/2019 - 07/2013
2	Sepsis (Septicemia) 05/2017 - 01/2017
2	Pneumonia (Pneumonitis) 05/2017 - 01/2017
2	Thrombosis (Thrombus) 01/2017 - 06/2006
2	Nausea 01/2017 - 04/2012
2	Diarrhea 01/2017 - 04/2012
2	Weight Loss (Weight Reduction) 07/2013 - 11/2011
2	Venous Thrombosis (Deep-Vein Thrombosis) 06/2013 - 06/2006
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 03/2012 - 08/2004
2	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 06/2007 - 11/2006
2	Portal Hypertension 07/2006 - 08/2005
2	Hepatomegaly 02/2006 - 02/2005
2	Osteosclerosis 01/2006 - 07/2004
1	COVID-19 01/2022

Drug/Important Bio-Agent (IBA)

45	ruxolitinibIBA 01/2022 - 09/2009
24	Janus Kinase InhibitorsIBA 01/2022 - 01/2013
12	fedratinibIBA 01/2022 - 09/2009
10	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 04/2021 - 04/2012
9	Syntex adjuvant formulationIBA 01/2022 - 07/2011
9	Hemoglobins (Hemoglobin)IBA 04/2021 - 04/2003
9	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 06/2020 - 04/2012
8	Pharmaceutical PreparationsIBA 06/2020 - 04/2003
8	Thalidomide (Thalomid)FDA Link 01/2011 - 05/2002
7	Janus KinasesIBA 01/2018 - 03/2012
6	Hydroxyurea (Hydrea)FDA LinkGeneric 12/2022 - 05/2008
6	Janus Kinase 2IBA 05/2021 - 03/2008
6	Proteins (Proteins, Gene)FDA Link 01/2021 - 08/2008
6	Janus Kinase 1IBA 12/2017 - 12/2013
6	CytokinesIBA 07/2015 - 05/2002
5	Phosphotransferases (Kinase)IBA 01/2020 - 07/2005
5	Lenalidomide (CC 5013)FDA Link 04/2012 - 08/2006
5	Prednisone (Sone)FDA LinkGeneric 01/2011 - 04/2003
4	pomalidomideIBA 01/2015 - 09/2009
4	Imatinib Mesylate (Gleevec)FDA Link 03/2013 - 05/2002
4	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 06/2007 - 04/2005
3	InterferonsIBA 12/2022 - 05/2011
3	CollagenIBA 01/2021 - 07/2004
3	Immunomodulating AgentsIBA 07/2017 - 01/2010
3	Erythropoietin FDA Link 01/2013 - 08/2002
3	Cytarabine (Cytosar-U)FDA LinkGeneric 03/2012 - 07/2005
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008 - 03/2002
2	IronIBA 04/2021 - 01/2015
2	Decitabine FDA Link 10/2020 - 12/2018
2	CreatinineIBA 10/2017 - 08/2015
2	Azacitidine (5 Azacytidine)FDA Link 10/2015 - 01/2015
2	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 04/2014 - 06/2013
2	adavosertibIBA 04/2014 - 03/2012
2	Checkpoint Kinase 1IBA 11/2011 - 07/2005
2	17-aminogeldanamycinIBA 11/2011 - 07/2005
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 11/2011 - 07/2005
2	tanespimycin (17AAG)IBA 11/2011 - 07/2005
2	Biological ProductsIBA 05/2011 - 01/2005
2	DNA (Deoxyribonucleic Acid)IBA 03/2008 - 11/2006
2	Etanercept (Enbrel)FDA Link 08/2002 - 03/2002
1	peginterferon alfa-2a (Pegasys)FDA Link 01/2022
1	dimemorfan (AT 17)IBA 01/2022
1	Danazol (Azol)FDA LinkGeneric 04/2021
1	Long Noncoding RNAIBA 01/2021
1	GATA1 Transcription FactorIBA 01/2021
1	NucleophosminIBA 01/2021
1	Nuclear Proteins (Protein, Nuclear)IBA 01/2021

Therapy/Procedure

72	Therapeutics 12/2022 - 02/2002
8	Stem Cell Transplantation 11/2019 - 08/2003
6	Erythrocyte Transfusion 12/2017 - 07/2004
4	Drug Therapy (Chemotherapy) 12/2014 - 05/2003
4	Splenectomy 07/2006 - 05/2003
3	Transplantation 10/2020 - 08/2011
3	Cell Transplantation 10/2020 - 11/2015
3	Radiotherapy 12/2018 - 10/2003
3	Immunomodulation 12/2013 - 09/2009
2	Hematopoietic Stem Cell Transplantation 01/2019 - 02/2006
1	Resistance Training 12/2020